·ÅÉäÖÎÁÆ,radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ªÎ÷Ëû±õ,gemcitabineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÇÐÎϸ°ûÁö,astrocytomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÅÉäÃô¸ÐÐÔ,RadiosensitivityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½ºÖÊÁö,gliomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖØÁ¿,WeightÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û¶¾×÷ÓÃ,cytotoxicityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ë®ÌýÆ÷,hydrophoneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶òÂåÌæÄá,ErlotinibÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍÐÈðÃ×·Ò,ToremifeneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÒÖËØ,tumstatinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ɱÉË»îÐÔ,Killing activityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÓÒÐýÄûÏ©,D-limoneneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÄÚƤÉú³¤Òò×ÓÊÜÌå-3,vascular endothelial growth factor receptor-3Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û¶¾ÐÔ×÷ÓÃ,cytotoxicityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÎÂÈÈÁÆ·¨,thermotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« żÁªÎï,conjugateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃÀ·¨ÂØ,melphalanÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö/Á÷Ðв¡Ñ§,neoplasms/epidemiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÒÍéÎøßø,EthaselenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶à¿Ë¡,PolyclonalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 188Re,~(188)ReÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫϸ°ûÉú³É,hematopoiesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µÍζ³´æ,cryopreservationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈÈ×Ñ,ThermoseedÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« º£ÉúËØ,HaishengsuÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Á¢ÌåÒì¹¹ÏÖÏó,StereoisomerismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½âÀëËØ,disintegrinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °©¿¹Ô­125,CA125Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ¥½¹µã,MonofocalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 18F-ÍÑÑõÆÏÌÑÌÇ,18F-FDGÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³ÉÁöÐÔ,tumorigenicityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñõ»¯ßÅßáÑÜÉúÎï,oxindolesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µåÓñºì¼×ë¿,Indirubin-3'-monoximeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÝÆ,terpenoidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˶ËÁ£Ã¸´ß»¯ÑÇ»ù,hTERTÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹í±Ê»·ëÄ,phalloidinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²»ÈÜÐÔ¦Â-ÆϾÛÌÇ,CAIBGÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·øÉäÔöÃô,radiosensitizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« exosome,exosomesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼×Ì¥µ°°×(AFP),alpha-fetoprotein(AFP)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±íÑõ»¯Ã¸,epoxygenaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÜ°ÍÉú³É,lymphangiogenesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö»µËÀÒò×ÓÏà¹ØÓÕµ¼µòÍöÅäÌå,TRAILÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢ÐÍË«¹¦ÄÜ¿¹Ìå,DiabodyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌåÄÚÉúÎï·Ö²¼,BiodistributionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃâÒß¼àÊÓ,immune surveillanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ÔÍÌÊÉ,AutophagyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ˿״¼¡¶¯µ°°×,F-actinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¤¹âɨÃèϸ°ûÒÇ,LSCÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ã¶«/Á÷Ðв¡Ñ§,guangdong/epidemiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËÖ×Áö»µËÀÒò×Ó,hTNF¦ÁÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« aurora-A»ùÒò,aurora-AÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½­ËÕ/Á÷Ðв¡Ñ§,Jiangsu/epidemiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿ÅÁ£µ°°×Ç°Ìå,ProgranulinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹â»ÔùËØ,mithramycinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ÏÌ´ËØ,pterocarpinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 1,2,4-±½Èý´¼,hydroxy-hydroquinonÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 188ïª,rhenium-188Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« É߶¾½â¾ÛËØ,ContortrostatinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« BCl3,BCl_3Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÇÀë×Ó±íÃæ»îÐÔ¼ÁÅÝÄÒ,niosomeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿µÆÕÈð¶¡Á×Ëá¶þÄÆ,CA-4PÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 14-3-3¦Â»ùÒò,14-3-3¦ÂgeneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ά¼×ËáÄÍÒ©,ATRA-resistanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏßÁ£ÌåÈÚºÏËØ»ùÒò-2,mitofusin-2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û±íÃæÁ×ËữÌǵ°°×,CD_(34)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ÅÏØ,CixianÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËÀà±íƤÉú³¤Òò×ÓÊÜÌå,erbBsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éñ¾­ÓªÑøÒò×Ó4,neurotrophinª²4Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« »¥¸ô½»Á´æßùËØ,AltenueneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DNAÒÀÀµµ°°×¼¤Ã¸(DNA-PK),DNA-PKÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´×ËáÇúÆ×ÈðÁÖ,alarelinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« SIRP¦Á,SIRPaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Eca-9706ϸ°û,Eca-9706Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« TNFR·â±Õ»·ëÄ,TNF-BPÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºÚÉ«ËØÁö¿¹Ô­-4,MAGE-4Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« pro-EMAP¢òµ°°×,pro-EMAP¢òproteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ELRÐòÁÐ,ELR-sequenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¯ºÏ»ùÒò,metageneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐØÏÙëĦÁ1(T¦Á1),Thymosin¦Á1(T¦Á1)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±í°¢Ã¹ËØ(EPI),Epirubicin(EPI)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ã×ÍÐÝìõ«(MIT),mitoxantone(MIT)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÆÍøµ°°×(CRT),calreticulin(CRT)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³¬ÉùÃô¸Ð,ultrasonic-sensitiveÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 7,12-¶þ¼×»ù±½Ýì,7,12-DMBAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÎëÄ,ACBP-LÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Æ¢ëÄ,ACBP-SÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »·(4-ôǸ¬-ÁÁ)¶þëÄ,cyclo-(4-hydroxy-Pro-Leu)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« RGD¶àëĽáºÏÐÍ°¢¿ËÀ­Ã¹ËØA³¤Ñ­»·Ö¬ÖÊÌå,RGD-ACM-A-LiposomeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÎøËáõ¥¶àÌÇ(KSC),Kappa-selenocarrageenan(KSC)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö/¶ñÐÔ,neoplasms/malignantÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃâÒß°ÐÏò,Immuno-targetingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 5-ÔÓµª-2'-ÍÑÑõ°ûà¤,5-aza-2'deoxycytidineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Gµ°°×Ðźŵ÷½Úµ°°×5(RGS5),RGS5Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Áܰ͹ÜÄÚƤ×æϸ°û,LEPCsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò¶ËáżÁª,folate-conjugatedÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöѪ¹ÜÒÖÖÆëÄ,AlphastatinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ó¦¼¤/ÐÄÀíѧ,stress/psychologicalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÂÉúѪ¹Ü»¯/²¡ÀíÐÔ,neovascularization/pathologicÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
 1 2 3 4 5 6 7 8 ÉÏÒ»Ò³